1 Department of Biochemistry and Molecular Biology and 3 Joint UCL/LICR X-Ray Crystallography Laboratory, University College London, Gower Street, London WC1E 6BT and 6 Pharmaceutical Optical Spectroscopy Centre, Department of Pharmacy, King's College London, Manresa Road, London SW3 6LX, UK
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Keywords: crystallography/ligand specificity/mutation/protein evolution/small molecule binding protein
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Structurally, AmiC is a two-domain protein related to periplasmic small-molecule binding proteins (SMBPs) such as the Escherichia coli branched amino acid binding protein, LivJ (Sack et al., 1989). The crystal structure of an AmiCacetamide complex determined at 2.1 Å resolution, precisely defined the amide binding site in AmiC (Pearl et al., 1994
), which lies at the interface of the two domains, which are stabilized in a `closed' conformation by contacts with the bound ligand. This closed-down acetamide-bound form of AmiC represents the `on' configuration of the regulatory system, in which AmiR is free to interact with the leader RNA of the operon transcript, and permit full expression. The mechanism of amide-switched regulation of AmiR by AmiC remains to be determined, but it probably involves disruption of a silencing AmiCAmiR complex on binding of inducing amides to AmiC (Wilson et al., 1996
).
Amidase expression in the PAC1 strain of P.aeruginosa is strongly induced by acetamide (one carbon chain) and lactamide or propionamide (two carbon chain) but not by butyramide (three carbon chain), which instead acts as an anti-inducer in vivo and competes for binding to AmiC in vitro. Thus, lengthening of the aliphatic chain by a single carbon converts a strong agonist into an antagonist. We have now cloned and sequenced AmiC from the PAC181 strain of P.aeruginosa, which was generated by classical in vivo selection for its ability to induce amidase expression in the presence of butyramide (Turberville and Clarke, 1981). The crystal structure of the AmiC protein from this mutant strain reveals the subtle structural adaptation that enables the butyramide-inducible phenotype, again demonstrating the remarkable adaptability of the `small molecule binding protein' fold to the specific recognition of ligands.
![]() |
Material and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The genes amiC and amiR were amplified by PCR from PAC181 chromosomal DNA using the oligonucleotides CRA (ATCCGAATTCTCACAGGAGAGGAAACGGATG) and CRL (CCGATGCCGAAGCCTTGATGACGATACCCCTCTT), (Genosys, Cambridge, UK) and Taq DNA polymerase. The amplified DNA fragment was isolated from a preparative agarose gel, cloned initially into pUC19 (pSW181) and characterized by restriction enzyme mapping. The 1.8 kb amiCR fragment was then subcloned into the broad host range vector pMMB66EH (Temple et al., 1990) (plasmid pSW1181) and mobilized from E.coli S17-1 into P.aeruginosa PAC327 (amiC, amiR). Amidase activity was determined in intact cells under non-inducing, inducing and repressing conditions as described previously (Drew, 1984
) and the results presented are the mean values of duplicate assays carried out on at least three separate occasions. One unit represents 1 µM acethydroxamate formed per min. Specific activities are units per mg of bacterial cells.
The nucleotide sequence of the amiC and amiR genes was determined by double-stranded sequencing using pSW181 as template as described previously (Wilson and Drew, 1991). Identification of mutations was facilitated by running parallel sequencing reactions of the PAC1 amiC and amiR genes.
Protein expression and purification
The mutant AmiC protein was isolated from P.aeruginosa strain PAC452 harbouring the plasmid pSW1181. Protein was overexpressed and purified essentially as described (Wilson et al., 1991), but with 5 mM butyramide (Sigma) present in the culture medium and maintained in all buffers during purification. The mutant PAC181 AmiC protein is much less easily handled than the wild type, and the omission of butyramide from the growth medium and isolation buffers significantly decreased the solubility of the mutant AmiC and prevented effective purification.
Crystallization of PAC181-AmiCbutyramide complex
The solubility profile of the PAC181-AmiC protein in the presence of butyramide proved to be significantly different from that for the PAC1-AmiC with acetamide (Wilson et al., 1991), and a new crystallization condition was identified using a sparse matrix screen (Jancarik and Kim, 1991
). Crystals of diffraction quality were eventually obtained from micro-batch experiments containing 12.8 mg/ml PAC181-AmiC, 5 mM butyramide, 1.36 M sodium citrate and 100 mM HEPES-NaOH (pH 7.5), implemented under paraffin oil in Terasaki dishes (Chayen et al., 1992
).
X-Ray data collection, processing and refinement
Diffraction data to 2.7 Å resolution were collected at 100 K from a single PAC181-AmiCbutyramide co-crystal, cryoprotected by soaking in 1.5 M sodium citrate, 100 mM HEPES-NaOH and 25% (v/v) glycerol, on a 30 cm MAR Image Plate detector mounted on a Rigaku RU200 rotating anode X-ray generator. Diffraction images were integrated using the MOSFLM package (Leslie, 1995) and reduced using the SCALA, AGROVATA and TRUNCATE programs of the CCP4 Suite (CCP4, 1994
). The scaled and merged data consist of 10 102 unique reflections, 97.8% complete in the range 38 to 2.7 Å (97.2% in the outer shell), with an average of 2.7 observations per reflection, and a merging R-factor of 0.098 (0.185 in the outer shell). Although the crystallization conditions for PAC181-AmiC with butyramide differ significantly from those for PAC1-AmiC with acetamide, the space group of the crystals is the same (P42212), and unit cell parameters (a, 104.15 Å; c, 65.68 Å) are very similar. Initial models were obtained by simulated annealing refinement of the coordinates (PDB code: 1PEA) for the PAC1-AmiCacetamide complex (Pearl et al., 1994
) against the PAC181-AmiCbutyramide complex data, using X-PLOR (Brunger, 1992
), but with coordinates for the bound acetamide and solvent molecules omitted from the start model, and residue 106 modelled as alanine. Difference electron density maps were calculated with
A-weighted coefficients to minimize model bias (Read, 1986
), and examined using `O' (Jones et al., 1991
). Subsequent simulated annealing and conjugate gradient refinement produced the current model consisting of 370 residues, 57 solvent molecules and a butyramide ligand. The crystallographic R-factor is 0.24 and the free-R factor with 5% of the data omitted from refinement is 0.30. The geometric parameters of the model are within the ranges expected at this resolution (Laskowski et al., 1993
). Coordinates have been deposited in the Protein Data Bank with accession code 1QNL.
CD spectroscopy
Near-UV circular dichroism signals were measured on a nitrogen flushed Jasco J720 spectrapolarimeter. Measurements were made with protein concentrations of 0.4 mg/ml and ligand concentrations of 10 mM using a 1 cm pathlength cuvette. The CD signal at 289 nm was measured as a function of temperature and fit to a van't Hoff equation (Freeman et al., 1998). The PAC1-AmiCacetamide complex displayed a Tm of 84°C; the PAC1-AmiCbutyramide complex a Tm of 79°C and the PAC181-AmiCbutyramide complex a Tm of 59°C.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Amidase activities were determined for P.aeruginosa strains PAC1 (wild-type), PAC181 (butyramide inducible), PAC327 (amiCR) and for PAC327 harbouring the plasmid pSW1181, which contains the 1.8 kb amiCR fragment amplified from PAC181 (see Materials and methods). PAC1 displayed characteristic lactamide inducibility, and PAC181 displayed lactamide and butyramide inducibility as previously described (Turberville and Clarke, 1981), but with lactamide inducibility at a lower level than in PAC1 (Table I
). Despite the regulatory negative phenotype, there is some residual background amidase activity detectable in PAC327, but no induction is observed in the presence of lactamide or butyramide. PAC327 harbouring pSW1181 shows substantial induction of amidase activity in the presence of lactamide or butyramide, confirming that the butyramide inducible phenotype was retained in the cloned PAC181 amiCR fragment. Nucleotide sequencing of the entire fragment revealed only a single mutation from the wild-type PAC1 sequence, a C
A transversion at position 317 in the amiC gene.
|
Earlier studies of the amidase operon had demonstrated that the responsiveness to amide inducers was a function of the AmiC protein (Wilson et al., 1993). Phenotypic changes in the response to specific amides by mutant strains would therefore be expected to be accompanied by mutations in the AmiC protein rather than in other components of the operon. The nucleotide sequence of the amiC gene from the butyramide-inducible strain P.aeruginosa PAC181 revealed a single base change relative to the wild-type amiC gene sequence, resulting in the replacement of a threonine residue at 106 in the PAC1-AmiC sequence (SwissProt entry AMIC_PSEAE) with an asparagine. As residue 106 is located close to the amide binding site at the interface of the N- and C-terminal domains of AmiC (Pearl et al., 1994
), a mutation in this residue would be consistent with a change in amide ligand specificity (Figure 1
).
|
|
|
In the wild-type PAC1-AmiC, the side-chain -hydroxyl group of Thr106 is hydrogen bonded to the peptide oxygen of Cys82 and weakly (3.2 Å), to the side-chain amide of Gln27. The
-methyl of Thr106 is directed towards the amide-binding pocket, but does not make any direct contact with the bound acetamide in that complex. In the mutant PAC181-AmiC, the side chain of the Asn106 is orientated so that its CßC
bond bisects the direction of the
-hydroxyl and
-methyl of the Thr106 in the PAC1-AmiC. The amide nitrogen in the head group of Asn106 picks up the hydrogen bond to the peptide oxygen of Cys82, and makes a strong hydrogen bond (2.7 Å) to the amide head group of Gln27, which changes conformation to make this interaction. Thus, the substitution of Asn for Thr at 106 retains the hydrogen bonding interactions made by Thr106 in the wild-type PAC1-AmiC. However, the amide oxygen of Asn106 in the PAC181 mutant is left buried in a hydrophobic environment, packed against the side chain of Tyr83, and with no hydrogen bonds to the rest of the protein, or to any solvent molecules. The burial of this polar group without any compensating interactions would be expected to be highly unfavourable. Consistent with this, the melting temperature (Tm) measured by near-UV CD (see Materials and methods) for denaturation of PAC181-AmiC with butyramide bound is down-shifted 20 K compared with the Tm of the PAC1-AmiC with butyramide, which is a poor ligand for the wild-type AmiC. Compared with the Tm for PAC1-AmiC with bound acetamide, an optimal ligand, the Tm for PAC181-AmiC with butyramide is decreased by 25 K (Figure 4
).
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In adapting to butyramide induction via the Thr106Asn mutation, PAC181-AmiC undergoes a significant decrease in its thermostability compared with wild type, and its half-life in vivo would be expected to be correspondingly shorter. However, the selective pressure to which the PAC181-AmiC sequence is a response, requires only that the amidase operon be inducible by butyramide. Thus, so long as the mutant AmiC can be synthesized at a sufficient level, fold and fulfil its biological role, its absolute structural stability need not be optimal. It is protein function that is selected in evolution, not structural stability, a fact often neglected in theoretical analyses of protein structure.
![]() |
Acknowledgments |
---|
![]() |
Notes |
---|
4 Present address: Department Biomolecular Sciences, UMIST, PO Box 88, Manchester M60 1QD, UK
5 Present address: Section of Structural Biology, Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UK
7 To whom correspondence should be addressed; email: l.pearl{at}icr.ac.uk
Bernard P.O'Hara and Stuart A.Wilson contributed equally to this work
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
CCP4 (1994) Acta Crystallogr., D50, 760763.[ISI]
Chayen,N.E., Stewart,P.D.S. and Blow,D.M. (1992) J. Cryst. Growth, 122, 176180.[ISI]
Clarke,P.H. and Drew,R. (1988) Bioscience Rep., 8, 103120.[ISI][Medline]
Drew,R. and Lowe,N. (1989) J. Gen. Microbiol., 135, 817823.[ISI][Medline]
Drew,R.E. (1984) J. Gen. Microbiol., 130, 31013111.[ISI][Medline]
Freeman,D.J., Pattenden,G., Drake,A.F. and Siligardi,G. (1998) J. Chem. Soc. Perkin, 2, 129135.
Jancarik,J. and Kim,S.H. (1991) J. Appl. Crystallogr., 24, 409411.[ISI]
Jones,T.A., Zou,J.-Y., Cowan,S.W. and Kjeldgaard,M. (1991) Acta Crystallogr., A47, 110119.[ISI]
Kelly,M. and Clarke,P.A. (1962) J. Gen. Microbiol., 27, 305316.[ISI]
Laskowski,R.A., Macarthur,M.W., Moss,D.S. and Thornton,J.M. (1993) J. Appl. Crystallogr., 26, 283291.[ISI]
Leslie,A.G.W. (1995) MOSFLM Users Guide. MRC Laboratory of Molecular Biology, Cambridge.
Pearl,L.H., O'Hara,B.P., Drew,R.E. and Wilson,S.A. (1994) EMBO J., 13, 58105817.[Abstract]
Read,R.J. (1986) Acta Crystallogr., A42, 140149.[ISI]
Sack,J.S., Saper,M.A. and Quiocho,F.A. (1989) J. Mol. Biol., 206, 171191.[ISI][Medline]
Temple,L., Cuskey,S.M., Perkins,R.E., Bass,R.C., Morales,N.M., Christie,G.E., Olsen,R.H. and Phibbs,P.V. (1990) J. Bacteriol., 172, 63966402.[ISI][Medline]
Turberville,C. and Clarke,P.H. (1981) FEMS Microbiol. Lett., 10, 8790.[ISI]
Wilson,S. and Drew,R. (1991) J. Bacteriol., 173, 49144921.[ISI][Medline]
Wilson,S.A., Chayen,N.E., Hemmings,A.M., Drew,R.E. and Pearl,L.H. (1991) J. Mol. Biol., 222, 869871.[ISI][Medline]
Wilson,S.A., Wachira,S.J., Drew,R.E., Jones,D. and Pearl,L.H. (1993) EMBO J., 12, 36373642.[Abstract]
Wilson,S.A., Wachira,S.J.M., Norman,R.A., Pearl,L.H. and Drew,R.E. (1996) EMBO J., 15, 59075916.[Abstract]
Received May 10, 1999; revised November 10, 1999; accepted November 16, 1999.